name	nt_name	aa_name	multi_aa_name	multiaa_comb_mutation	start	vcf_gene	chrom_region	mutation_type	sequence_depth	sample_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao	reference_seq	variant_seq	viral_lineages	function_category	citation	comb_mutation	function_description	heterozygosity	clade_defining	who_variant	status	voi_designation_date	voc_designation_date	vum_designation_date
c.C-233T	c.C-233T				33	orf1ab	5' UTR		9	477	mask	seq_end				8	1	C	T	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
c.C-25T	c.C-25T				241	orf1ab	5' UTR		477	477						0	477	C	T	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
c.C-44T	c.C-44T				222	orf1ab	5' UTR		471	477						5	466	C	T	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
c.C-63T	c.C-63T				203	orf1ab	5' UTR		475	477						5	470	C	T	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
p.A308A	c.C924T	p.A308A			29197	N	N	SILENT	476	477						5	471	C	T	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
p.C3563C	c.C10689T	p.C3563C			10954	orf1ab	ORF1ab	SILENT	476	477			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	5	471	C	T	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
p.C5332C	c.C15996T	p.C5332C			16260	orf1ab	ORF1ab	SILENT	476	477			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	368	108	C	T	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	ACE2 receptor binding affinity	Gong et al. (2021)	'P681H'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	ACE2 receptor binding affinity	Li et al. (2020)		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	convalescent plasma binding	Gong et al. (2021)	'P681H'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	immunosuppression variant emergence	Landis et al. (2021)		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	syncytium formation	Kim et al. (2021)		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	tissue specific neutralization	Planas et al. (2021)		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	trafficking	Barrett et al. (2021)		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	trafficking	Daniloski et al. (2021)		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	trafficking	Kim et al. (2021)		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	trafficking	Kim et al. (2021)		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	trafficking	Ozono et al. (2020)		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	trafficking	Zhang et l. (2020)		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	vaccine neutralization efficacy	Kuzmina et al. (2021)		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	vaccine neutralization efficacy	Zuckerman et al. (2021)	'P681H'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	vaccinee plasma binding	Gong et al. (2021)	'P681H'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	viral load	Plante et al. (2020)		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	virion structure	Weissman et al. (2020)		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	virion structure	Yurkovetskiy et al. (2020)		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	True	Unnamed	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	477	477						0	477	A	G	B.1.1.519	virion structure	Zhang et al. (2020)		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	True	Unnamed	VUM			02-Jun-2021
p.E748Q	c.G2242C	p.E748Q			23804	S	S	MISSENSE	477	477						409	68	G	C	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.F924F	c.C2772T	p.F924F			3037	orf1ab	ORF1ab	SILENT	477	477			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	477	C	T	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
p.G1451G	c.C4353T	p.G1451G			4618	orf1ab	ORF1ab	SILENT	477	477			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	416	61	C	T	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.H1160H	c.T3480C	p.H1160H			3745	orf1ab	ORF1ab	SILENT	477	477			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	368	109	T	C	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.H1974H	c.C5922T	p.H1974H			6187	orf1ab	ORF1ab	SILENT	477	477			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	390	87	C	T	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.I201V	c.A601G	p.I201V			866	orf1ab	ORF1ab	MISSENSE	477	477			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	262	215	A	G	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.I3618V	c.A10852G	p.I3618V			11117	orf1ab	ORF1ab	MISSENSE	477	477			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	5	472	A	G	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
p.L4P	c.T11C	p.L4P			27904	ORF8	ORF8	MISSENSE	477	477						256	221	T	C	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.L766I	c.T2296A	p.L766I			2561	orf1ab	ORF1ab	MISSENSE	477	477			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	409	68	T	A	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.N211D	c.A631G	p.N211D			22193	S	S	MISSENSE	477	477						264	213	A	G	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.N36Y	c.A106T	p.N36Y			29663	ORF10	ORF10	MISSENSE	476	477						368	108	A	T	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.N6525N	c.T19575C	p.N6525N			19839	orf1ab	ORF1ab	SILENT	476	477			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	5	471	T	C	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
p.P1640S	c.C4918T	p.P1640S			5183	orf1ab	ORF1ab	MISSENSE	477	477			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	262	215	C	T	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.P4715L	c.C14144T	p.P4715L			14408	orf1ab	ORF1ab	MISSENSE	477	477			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	477	C	T	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	477	477						3	473	C	A	B.1.1.519	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	True	Unnamed	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	477	477						3	473	C	A	B.1.1.519	antibody epitope effects	Chen et al. (2021)		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	True	Unnamed	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	477	477						3	473	C	A	B.1.1.519	antibody epitope effects	Haynes et al. (2021)		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	True	Unnamed	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	477	477						3	473	C	A	B.1.1.519	antibody epitope effects	Johnson et al. (2020)		This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.	False	True	Unnamed	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	477	477						3	473	C	A	B.1.1.519	convalescent plasma binding	Gong et al. (2021)	'D614G'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Unnamed	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	477	477						3	473	C	A	B.1.1.519	trafficking	Lubinski et al. (2021)		While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).	False	True	Unnamed	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	477	477						3	473	C	A	B.1.1.519	trafficking	Maaroufi (2021)		This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).	False	True	Unnamed	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	477	477						3	473	C	A	B.1.1.519	trafficking	Tada et al. (2021)		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern. 	False	True	Unnamed	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	477	477						3	473	C	A	B.1.1.519	vaccine neutralization efficacy	Zuckerman et al. (2021)	'D614G'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	True	Unnamed	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	477	477						3	473	C	A	B.1.1.519	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Unnamed	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	477	477						3	473	C	A	B.1.1.519	virion structure	Tada et al. (2021)		The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	True	Unnamed	VUM			02-Jun-2021
p.P959S	c.C2875T	p.P959S			3140	orf1ab	ORF1ab	MISSENSE	476	477			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	5	471	C	T	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
p.Q56X	c.C166T	p.Q56X			27367	ORF6	ORF6	NONSENSE	477	477						422	55	C	T	B.1.1.519	IFN activity	Kimura et al. (2020)		The residues listed are determinants of the potent IFN-antagonistic activity of SARS-CoV-2 ORF6 (via blocking mRNA nuclear export)	False	False	Unnamed	VUM			02-Jun-2021
p.R5497R	c.A16491G	p.R5497R			16755	orf1ab	ORF1ab	SILENT	476	477			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	368	108	A	G	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.R7014R	c.C21042T	p.R7014R			21306	orf1ab	ORF1ab	SILENT	476	477			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only	YP_009725311.1	5	471	C	T	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
p.RG203KR	c.GGG608_610AAC	p.RG203KR			28881	N	N		476	477						4	472	GGG	AAC	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
p.S197S	c.A591T	p.S197S			28864	N	N	SILENT	477	477						264	213	A	T	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.S248S	c.C744T	p.S248S			1009	orf1ab	ORF1ab	SILENT	477	477			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	262	215	C	T	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.S2547S	c.A7641G	p.S2547S			7906	orf1ab	ORF1ab	SILENT	477	477			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	390	87	A	G	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.S3884L	c.C11651T	p.S3884L			11916	orf1ab	ORF1ab	MISSENSE	477	477			nsp7	produced by both pp1a and pp1ab	YP_009725303.1	262	215	C	T	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.T151I	c.C452T	p.T151I			25844	ORF3a	ORF3a	MISSENSE	477	477						368	109	C	T	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.T170I	c.C509T	p.T170I			774	orf1ab	ORF1ab	MISSENSE	477	477			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	390	87	C	T	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.T2183I	c.C6548T	p.T2183I			6813	orf1ab	ORF1ab	MISSENSE	477	477			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	421	56	C	T	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.T269T	c.G807A	p.T269T			26199	ORF3a	ORF3a	SILENT	477	477						264	213	G	A	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.T3255I	c.C9764T	p.T3255I			10029	orf1ab	ORF1ab	MISSENSE	477	477			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	5	472	C	T	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
p.T4175I	c.C12524T	p.T4175I			12789	orf1ab	ORF1ab	MISSENSE	469	477			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab	YP_009725305.1	4	465	C	T	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
p.T4304I	c.C12911T	p.T4304I			13176	orf1ab	ORF1ab	MISSENSE	477	477			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab	YP_009725306.1	264	213	C	T	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
p.T478K	c.C1433A	p.T478K			22995	S	S	MISSENSE	476	477						5	471	C	A	B.1.1.519	immunosuppression variant emergence	Choi et al. (2020)		Combination of RBD mutations appeared (day 75) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome complicated by diffuse alveolar hemorrhage, who was receiving anticoagulation therapy, glucocorticoids, cyclophosphamide, and intermittent rituximab and eculizumab. 	False	True	Unnamed	VUM			02-Jun-2021
p.T732A	c.A2194G	p.T732A			23756	S	S	MISSENSE	477	477						5	472	A	G	B.1.1.519					False	True	Unnamed	VUM			02-Jun-2021
p.V5721A	c.T17162C	p.V5721A			17426	orf1ab	ORF1ab	MISSENSE	477	477			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	390	87	T	C	B.1.1.519					False	False	Unnamed	VUM			02-Jun-2021
